Disruption on the way for Sonic Healthcare

Disruption on the way for Sonic Healthcare. Sonic is the largest pathology company in Australia and Germany, and the third largest in the US. The business generated $3.5 billion in revenue and $340 million in NPAT in 2013 and employs thousands of pathologists, medical scientists and technicians. You wouldn't think a company like Sonic in such a stable industry could be at threat. Then along comes 19-year-old chemical engineer Elizabeth Holmes and Theranos - the biggest blood diagnostic company you've never heard of. A recent $400m venture capital raising effectively gave the company a $US9bn valuation - eclipsing Sonic Heathcare's capitalisation of $6.8bn. It's more than a start up and its run by a young woman with that change-the-world zeal'' seen in the likes of Steve Jobs and Bill Gates. Theranos's technology is highly disruptive, offering multiple, simultaneous blood-diagnostic tests from just a few drops. Worth reading: (VIEW LINK) & (VIEW LINK)

2 topics

The Livewire Equities feed brings you a range of insights that relate to Australian equities


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.